BEVERLY, Mass., June 18, 2008 – Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company’s selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S. Food and Drug Administration to advance INO-8875 into clinical trials. The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients. Glaucoma patients typically have elevated levels of IOP which can damage the optic nerve of the eye and lead to partial or complete loss of vision. “We are pleased that our clinical program in glaucoma is progressing and I am encouraged by the strength of our preclinical data supporting the potential role of Adenosine 1 receptor agonists in managing intraocular pressure,” said Dr. Rudolf Baumgartner, Inotek’s Chief Medical Officer. “New mechanisms for lowering IOP are needed […]

Read more →